Cervical Cancer (Human Papillomavirus - HPV)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
Cervical Cancer (Human Papillomavirus - HPV) is a type of cancer that affects the cervix, which is the lower part of the uterus connecting to the vagina. It is primarily caused by persistent infection with high-risk types of HPV, a common sexually transmitted virus. This cancer develops slowly over time, often starting with abnormal cell changes that can be detected early. If untreated, these changes can progress to invasive cancer, which may cause symptoms like abnormal vaginal bleeding or pelvic pain. The disease mainly impacts the female reproductive system and can affect overall health by spreading to nearby tissues or distant organs. Early detection through screening is crucial because it allows treatment before cancer becomes advanced. Understanding the role of HPV infection is key to preventing and managing this condition.
Clinical Definition
HPV-associated cervical cancer is an invasive squamous carcinoma or adenocarcinoma arising in the cervix after persistent high-risk HPV infection, especially types16 and18. E6 promotes p53 degradation; E7 inactivates Rb and releases E2F, favoring cell-cycle progression. Viral integration commonly promotes oncogene expression but is not required in every tumor. Most HPV infections resolve; persistent high-grade precursor lesions can progress over years. Stromal invasion through the basement membrane distinguishes invasive carcinoma from CIN or adenocarcinoma in situ. Pap/HPV tests screen for risk or abnormal cells; tissue establishes invasive disease. A minority of cervical cancers are HPV-independent.
Inciting Event
Infection with high-risk HPV strains is the initiating event for cervical carcinogenesis.
Acquisition of HPV occurs through sexual contact with an infected partner.
Latency Period
The latency period from initial HPV infection to invasive cervical cancer can be 10-20 years.
Most HPV infections and many low-grade lesions regress; persistent high-grade lesions can progress over years, more rapidly with immunosuppression. CIN1 does not inevitably progress through every grade.
Diagnostic Delay
Lack of regular Pap smear screening leads to delayed detection of precancerous changes.
Early cervical cancer is often asymptomatic, causing patients to present late.
Misattribution of symptoms like postcoital bleeding to benign causes delays diagnosis.
Clinical Presentation
Signs & Symptoms
Abnormal vaginal bleeding, including postcoital, intermenstrual or postmenopausal bleeding; early disease can be asymptomatic.
Intermenstrual or irregular vaginal bleeding often occurs
Watery, bloody vaginal discharge may be present
Pelvic pain or dyspareunia in advanced disease
Urinary symptoms such as frequency or obstruction if the tumor invades adjacent structures
History of Present Illness
Initial symptoms include intermittent postcoital bleeding and vaginal discharge.
Progression leads to irregular menstrual bleeding and pelvic pain.
Advanced disease may present with urinary symptoms or leg edema due to local invasion.
Past Medical History
History of persistent high-risk HPV infection or previous CIN lesions increases risk.
Prior immunosuppressive conditions such as HIV infection worsen prognosis.
Lack of HPV vaccination is a modifiable risk factor.
Family History
No strong familial inheritance pattern, but family history of cervical cancer may indicate shared environmental or behavioral risk factors.
Rarely, genetic predispositions affecting immune response to HPV may contribute.
Physical Exam Findings
Friable cervical lesions with irregular, exophytic, or ulcerative appearance on speculum exam
Cervical bleeding or contact bleeding upon examination
Pelvic/para-aortic nodal spread is assessed by imaging and, when indicated, pathology; these deep nodes are not reliably evaluated by routine palpation.
Parametrial induration or fixation indicating local invasion
Pelvic mass or irregular cervical contour on bimanual exam
Diagnostic Workup
Diagnostic Criteria
Biopsy demonstrating stromal invasion confirms invasive cervical carcinoma; colposcopy-directed biopsy or an excisional specimen is selected as appropriate. CIN/high-grade dysplasia alone is not invasive cancer. HPV positivity or viral integration is not a required stand-alone diagnostic test. Evaluate suspicious bleeding or a visible lesion even with negative screening. Clinical examination, imaging and pathology then establish extent and nodal involvement for staging.
Pathophysiology
Key Mechanisms
Persistent infection with high-risk HPV types 16 and 18 leads to expression of viral oncoproteins E6 and E7, which inactivate tumor suppressors p53 and Rb.
E6-mediated degradation of p53 impairs apoptosis and DNA repair, promoting genomic instability.
E7-mediated inactivation of Rb releases E2F transcription factors, driving uncontrolled cell cycle progression.
HPV integration may disrupt viral regulatory control and increase E6/E7 expression; it is common in cancer but is not obligatory, and is not a routine confirmatory test.
Chronic inflammation and immune evasion by HPV contribute to progression from cervical intraepithelial neoplasia (CIN) to invasive carcinoma.
| Involvement | Details |
|---|---|
| Organs | Cervix is the primary organ affected by HPV-induced malignant transformation leading to cervical cancer. |
Lymph nodes serve as common sites for regional metastasis and are important in staging. | |
Uterus may be involved in advanced disease with local extension of cervical cancer. | |
| Tissues | Cervical epithelium undergoes dysplastic changes progressing to invasive carcinoma in cervical cancer. |
Basement membrane integrity loss allows invasion of malignant cells into underlying stroma. | |
Lymphatic tissue adjacent to the cervix is a common site for early metastatic spread. | |
| Cells | Transformation-zone squamous epithelium gives rise to most cervical cancers; endocervical glandular epithelium gives rise to adenocarcinoma. |
Langerhans cells participate in antigen presentation and immune response to HPV infection. | |
T lymphocytes mediate immune surveillance and cytotoxic response against HPV-infected and transformed cells. | |
| Chemical Mediators | E6 and E7 oncoproteins from high-risk HPV types inactivate tumor suppressors p53 and Rb, driving carcinogenesis. |
Vascular endothelial growth factor (VEGF) promotes angiogenesis essential for tumor growth and metastasis. | |
Cytokines such as IL-6 and TNF-alpha contribute to the inflammatory microenvironment supporting tumor progression. |
Treatments
Pharmacological Treatments
Cisplatin
- Mechanism:
Forms DNA crosslinks causing apoptosis in rapidly dividing cancer cells.
- Side effects:
Nephrotoxicity
Ototoxicity
Peripheral neuropathy
Myelosuppression
- Clinical role:
Radiosensitizer with definitive radiation for appropriate locally advanced disease; also part of selected systemic combinations. Renal function and other toxicities influence suitability.
Paclitaxel
- Mechanism:
Stabilizes microtubules and inhibits mitosis leading to cancer cell death.
- Side effects:
Peripheral neuropathy
Myelosuppression
Hypersensitivity reactions
- Clinical role:
Component of platinum-based systemic combinations for persistent, recurrent or metastatic disease; not a universal first-line treatment for every stage.
Bevacizumab
- Mechanism:
Monoclonal antibody that inhibits VEGF, reducing tumor angiogenesis.
- Side effects:
Hypertension
Proteinuria
Thromboembolism
Impaired wound healing, serious bleeding and gastrointestinal or genitourinary fistula/perforation
- Clinical role:
Anti-VEGF option added to selected chemotherapy regimens for persistent/recurrent/metastatic disease; bleeding, fistula and wound-healing risks guide selection.
Topotecan
- Mechanism:
Inhibits topoisomerase I, causing DNA damage and apoptosis in cancer cells.
- Side effects:
Myelosuppression
Nausea
Fatigue
- Clinical role:
Selected recurrent/metastatic regimens, including paclitaxel-containing combinations; use depends on prior therapy and current options, not a universal second-line designation.
Pembrolizumab
- Mechanism:
PD-1 checkpoint-blocking antibody that enhances antitumor T-cell activity.
- Side effects:
Immune-mediated pneumonitis, colitis or hepatitis
Immune-mediated thyroid and other endocrine disorders
Infusion reactions
- Clinical role:
With chemoradiotherapy for FIGO2014 stageIII–IVA disease; also used in selected PD-L1-positive persistent/recurrent/metastatic disease with chemotherapy ± bevacizumab or after chemotherapy. Eligibility depends on the specific indication.
Non-pharmacological Treatments
Stage- and risk-based surgery: selected microinvasive cancers may be treated with conization; hysterectomy or fertility-preserving surgery is chosen for suitable early disease. Radical hysterectomy is not required for every early lesion.
Locally advanced disease commonly requires external-beam radiation plus brachytherapy with concurrent radiosensitizing chemotherapy; treatment is tailored by stage and patient factors.
Screening identifies people needing evaluation; it is not treatment for established invasive cancer. Confirmed disease requires gynecologic oncology care.
HPV vaccination prevents new infection and is not a treatment for existing HPV infection, CIN or invasive cancer.
Prevention
Pharmacological Prevention
Prophylactic HPV vaccination before exposure prevents vaccine-type infection. U.S. routine vaccination is age11–12 (may start9), catch-up through26, and shared decision-making for selected adults27–45.
Topical immune modulators are not routine cervical cancer prevention or treatment; they must not replace indicated evaluation or treatment of high-grade cervical lesions.
No routine antiviral medication eradicates established cervical HPV infection; manage abnormal results and precancer by an appropriate risk-based pathway.
Non-pharmacological Prevention
Use the current named screening guideline for average-risk, asymptomatic people with a cervix: ACOG starts cytology at21; ACS starts screening at25, preferring primary HPV testing. Test choice/interval, prior high-grade disease and immunosuppression matter. Vaccination does not eliminate screening, and symptoms require diagnostic evaluation outside screening schedules.
Condoms reduce but do not eliminate HPV transmission because uncovered skin can transmit infection; vaccination and screening remain important.
Smoking cessation to decrease cofactor risk
Early treatment of cervical intraepithelial neoplasia (CIN) to prevent progression
Public health education to increase HPV vaccine uptake and screening adherence
Outcome & Complications
Complications
Local invasion causing ureteral obstruction and hydronephrosis
Pelvic fistulas between the bladder, rectum, or vagina
Distant metastases to lungs, liver, or bone
Severe anemia from chronic bleeding
Infection and sepsis secondary to necrotic tumor tissue
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Cervical Cancer (Human Papillomavirus - HPV) versus Cervicitis
Cervical Cancer (Human Papillomavirus - HPV) | Cervicitis |
|---|---|
Persistent high-risk HPV is the major cause; multiple partners are not required. | May follow an STI exposure, but history alone neither confirms nor excludes cervicitis. |
Often silent until bleeding or discharge develops; symptoms overlap cervicitis. | Can be asymptomatic, acute or persistent; mucopurulent discharge and friability support inflammation. |
Biopsy establishes invasive squamous or glandular carcinoma; demonstrating viral integration is unnecessary. | NAAT for chlamydia/gonorrhea identifies common causes; negative tests do not exclude noninfectious or other infectious cervicitis. |
Cervical Cancer (Human Papillomavirus - HPV) versus Endometrial carcinoma
Cervical Cancer (Human Papillomavirus - HPV) | Endometrial carcinoma |
|---|---|
Often affects women aged 30-50 years with persistent HPV infection | Typically postmenopausal women aged >55 years |
Imaging can show a cervical-centered lesion, but small invasive cancers may be occult. | Endometrial thickening can prompt evaluation, but imaging alone does not establish cancer; endometrial tissue sampling is diagnostic. |
Invasive squamous or glandular carcinoma arising in the cervix; most are HPV-associated. | Carcinoma arising in endometrium, often endometrioid but other histologies occur; pathology establishes the primary site. |
Cervical Cancer (Human Papillomavirus - HPV) versus Vaginal cancer
Cervical Cancer (Human Papillomavirus - HPV) | Vaginal cancer |
|---|---|
Persistent high-risk HPV is the major etiologic exposure. | High-risk HPV is also a major cause of vaginal squamous cancer; prior vaginal neoplasia or other risks may be present. |
Tumor arises from cervical squamous or glandular epithelium with HPV oncogene expression | Tumor arises from vaginal squamous epithelium with possible HPV association |
Mass centered in the cervix with possible extension to adjacent structures | Mass localized to vaginal wall without cervical involvement |
Cervical Cancer (Human Papillomavirus - HPV) versus Benign cervical polyp
Cervical Cancer (Human Papillomavirus - HPV) | Benign cervical polyp |
|---|---|
May cause intermittent or persistent contact bleeding; symptom tempo alone is insufficient. | Often asymptomatic or causes spotting/contact bleeding; visual appearance and histology distinguish a polyp from malignancy. |
Malignant squamous or glandular epithelial cells with dysplasia and invasion | Polyp composed of benign endocervical glandular and stromal tissue |
Histology demonstrates stromal invasion; high-grade dysplasia alone is precancer. | Histology confirms benign polyp architecture; atypical-appearing or symptomatic lesions need appropriate evaluation. |
Cervical Cancer (Human Papillomavirus - HPV) versus Pelvic inflammatory disease (PID)
Cervical Cancer (Human Papillomavirus - HPV) | Pelvic inflammatory disease (PID) |
|---|---|
HPV-related cancer may coexist with an acute STI; absence of STI symptoms is not required. | Often associated with gonorrhea/chlamydia or vaginal flora; no known recent exposure does not exclude PID. |
May be asymptomatic or cause bleeding, discharge or pain. | Pelvic pain and cervical motion/uterine/adnexal tenderness suggest PID; fever can be absent and disease can be subtle. |
Inflammatory markers and HPV testing do not confirm or exclude cancer; biopsy is decisive. | Inflammatory markers and STI NAATs support assessment, but normal markers or negative cervical NAATs do not exclude upper genital tract infection. |